TRAIL and interferon-alpha act synergistically to induce renal cell carcinoma apoptosis.

Abstract

PURPOSE Despite modern targeted therapy metastatic renal cell carcinoma remains a deadly disease. Interferon-alpha (Calbiochem(R)) is currently used to treat this condition, mainly combined with the targeted anti-vascular endothelial growth factor antibody bevacizumab. TRAIL (Apo2 ligand/tumor necrosis factor related apoptosis inducing ligand) (Calbiochem… (More)
DOI: 10.1016/j.juro.2010.04.064

Topics

8 Figures and Tables

Cite this paper

@article{Clark2010TRAILAI, title={TRAIL and interferon-alpha act synergistically to induce renal cell carcinoma apoptosis.}, author={Peter E. Clark and Dina A Polosukhina and Kenneth Gyabaah and Harold L. Moses and Andrew Thorburn and Roy Zent}, journal={The Journal of urology}, year={2010}, volume={184 3}, pages={1166-74} }